GlassScriptPhysician profile
Jessica Evans
NPI 1629569934
$1,127.67
in general payments reported to CMS, 2019-2025
20 companies · $105 in 2025
The $105 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.75 · 2020: $62.46 · 2021: $146 · 2022: $409 · 2023: $362 · 2025: $105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $161.76 | 2021-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $127.34 | 2021-2023 | Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $105.92 | 2020-2022 | |
| Novo Nordisk INC | $93.47 | 2022-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $91.19 | 2019-2023 | |
| Exact Sciences Corporation | $71.53 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $66.22 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $51.95 | 2022-2023 | Eliquis |
| Abbott Laboratories | $44.14 | 2022-2023 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $43.71 | 2019-2020 | |
| Amgen INC. | $40.32 | 2023 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.57 | 2021-2023 | Xifaxan |
| Amarin Pharma, INC. | $34.44 | 2021-2022 | |
| Glaxosmithkline, LLC. | $29.20 | 2020 | |
| Eisai INC. | $28.02 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $26.25 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $25.53 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.62 | 2022 | |
| Daiichi Sankyo INC. | $16.34 | 2021 | |
| Merck Sharp & Dohme LLC | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.